Publications
484 publications
- Date
- Relevance
-
Taking care of good healthcare
-
Organisation chart 2024
This document gives an overview of the members of the Executive Board (RvB), the management of the National Health Care Institute ...
-
Advice - do not reimburse teclistamab (Tecvayli®) for the treatment of multiple myeloma
The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to not reimburse teclistamab ...
-
Advice - reimburse dostarlimab (Jemperli®) for the treatment of endometrial cancer
The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to reimburse dostarlimab ...
-
Advice - reimburse sacituzumab govitecan (Trodelvy®) for the treatment of breast cancer (re-evaluation)
The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to reimburse sacituzumab govitecan ...
-
Advice - reimburse naldemedine (Rizmoic®) for the treatment of constipation due to the use of strong analgesics (opioids)
The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to reimburse naldemedine (Rizmoic ...
-
Advice - extending the reimbursement of axicabtagene ciloleucel (Yescarta®) for the treatment of lymphoma
The National Health Care Institute has advised the Minister for Medical Care to extend the reimbursement of axicabtagene ...
-
Advice - do not reimburse loncastuximab tesirine (Zynlonta®) for the treatment of lymphoma
The National Health Care Institute has advised the Minister for Medical Care to not reimburse loncastuximab tesirine (Zynlonta®) ...
-
Advice - do not reimburse glofitamab (Columvi®) for the treatment of lymphoma
The National Health Care Institute has advised the Minister for Medical Care to not reimburse glofitamab (Columvi®) from the ...
-
Advice - reimburse pegunigalsidase alfa (Elfabrio®) for the treatment of Fabry disease
The National Health Care Institute has advised the Minister for Medical Care to reimburse pegunigalsidase alfa (Elfabrio®) from ...